Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge catalyst for May 6
“We have begun working with the Battery Innovation Center located in Indiana to retest and certify our solid-state battery,” said David Michery, CEO and chairman of Mullen Automotive. “BIC is a well-respected battery laboratory, and we look forward to publishing their results related to cell testing coming up in May.”
https://en.wikipedia.org/wiki/Hindenburg_disaster
Looks like they diluted at the morning and now it's ready to go. Added @0.64
BTC broke some support to the downside, not looking good for short term
Nice report besides this: " Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the
company in the past 12 months."
"2022 ATM Offering
On February 25, 2022, the Company entered into an At-The-Market issuance sales agreement with Ascendiant Capital to sell shares of common stock having an aggregate offering price of up to $200 million (the “2022 ATM Offering”). As of April 1, 2022, the Company had sold an aggregate of 146.0 million shares of common stock pursuant to the 2022 ATM Offering for gross proceeds of $114.6 million.
On March 30, 2022, the Company fully paid its $66 million senior secured notes and accrued interest. The 10% original issuance discount promissory notes were sold in December 2021 and were due and payable on March 31, 2022."
"Subsequent to December 31, 2021, on February 25, 2022, we entered into the 2022 Sales Agreement with Ascendiant to sell shares of common stock having an aggregate offering price of up to $200 million from time to time, through the 2022 ATM Offering. The offer and sale of shares of common stock from the 2022 ATM Offering was made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-260618) which became effective on November 12, 2021. As of March 31, 2022, the Company had sold an aggregate of 140.7 million shares of common stock pursuant to the 2022 ATM Offering for gross proceeds of $110.4 million. The shares were sold at an average price of $0.78 per share."
"On February 25, 2022, we entered into an At-The-Market Issuance Sales Agreement (the “2022 Sales Agreement”) with Ascendiant to sell shares of common stock having an aggregate offering price of up to $200 million from time to time, through an “at the market offering” program (the “2022 ATM Offering”). The offer and sale of shares of common stock from the 2022 ATM Offering was made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-260618) which became effective on November 12, 2021. Through March 31, 2022, we had received gross proceeds of approximately $110 million through the sale of 140,658,096 shares of common stock from the 2022 ATM Offering."
They can dilute more bud
Feb 25th, 2022 the recent ATM of up to $200M
$85.4M dilution remaining as of April 1,2022
Historic average dilution price per share of $0.78 it means roughly 109M more shares to be diluted to get full $200M.
With this current SS fair value of the company is around $1.83pps ($490M assets)
This company's value is at least 400M aka $4.8pps but let's dip 50 cents first
1900+ viewers waiting
Infinited Fiber, Spinnova's local competitor, private company so far..
Gap closed on daily chart
Vertical take-off in the making
All aboard with heavy bags
Like a Nile river of miners flowing to the moon!
From S-1
"As of March 23, 2022, there are 950,905,044 shares of Common Stock issued and outstanding. Kim Thompson, our founder and Chief Executive Officer, owns approximately 21.39% of our issued and outstanding Common Stock. As of March 23, 2022, there are 2 shares of super voting Series A Preferred Stock issued and outstanding, all of which are owned by Kim Thompson, which represent approximately 29.61% of all voting rights of our capital stock"
188,118,436 shares of Common Stock outstanding as of March 1, 2022
So they have diluted 153M/228M shares so far, 75M more dilution to come via Esousa. There will be around 263M common shares after dilution is complete.
Company will get around $157M cash from dilution, assuming Esousa is paying for $0.6877/share
Me too getting more @1.17
New target price $4.75
Looking good!
Spinnova H2/21
https://www.inderes.fi/fi/videot/spinnova-tilinpaatosinfo-242-klo-1130
(Wide monitor needed for decent viewing experience)
CEO Janne Poranen seems really exited about the future of the company.
You can use their fiber on skies for example. And recycle and use the same fiber again. Janne says it is the holy grail of materials :)
He talks a little about spider silk and proteins as well
Janne talks "rally English" but hope you understand still, they all are wearing new Adidas Terrex hoodies!
Enjoy!
Hoodie is out from Spinn, I have talked this before here, they are moving fast to production. No small shipment like kblb.
This is translated from today's Helsingin Sanomat newspaper:
"Sportswear giant Adidas launches hoodie with Finnish Spinnova fiber - this is what it looks like
According to Spinnova, the launch is a significant step in the commercialization of its textile fiber.
Spinnova and Adidas will introduce a new hoodie with Spinnova textile fiber on Thursday. Photo: Spinnova handout
Harri Pietarinen HS
13:44
Spinnova, which develops textile fibers, and Adidas, a German sportswear manufacturer, will present a new hoodie made of Spinnova material on Thursday.
The launch is a significant step in the commercialization of Spinnova, the company says in a press release. The garment will go on sale in early July. However, it will not have a “significant impact” on Spinnova’s financial performance this year.
The hoodie called Terrex HS is an intermediate layer garment designed for outdoor enthusiasts. Its knitted material is a blend of organic cotton and at least 25 percent wood-based Spinnova textile fiber.
Spinnova's first commercial-scale plant is scheduled for completion in Jyväskylä at the end of this year.
The company's partner in the Millspin mill is the Brazilian pulp company Suzano. The goal is for the partners to be able to produce one million tonnes of Spinnova fiber per year worldwide in 10 to 12 years.
Spinnova and Adidas announced their collaboration in June. Adidas joined Spinnova's IPO last June on the Helsinki Stock Exchange's First North marketplace."
Sorry, I was way off, current holdings:
Vanguard Group Inc ownership in HEPA / Hepion Pharmaceuticals Inc
2021-02-10 - Vanguard Group Inc has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,728,604 shares of Hepion Pharmaceuticals Inc (US:HEPA). This represents 5.96 percent ownership of the company.
HEPA Analyst Ratings
CONSENSUS
Strong Buy
Based on 2 analysts offering recommendations for hepa in the last 3 months.
Analyst Firms Making Recommendations
BROOKLINE CAP M
ROTH CAPITAL PA
Vanguard Group increasing to their position, they hold already quite a big position over 3.3M
Good signal!
Insiders buying and phase 3 data coming out soon, looking good for a little run
Dollar volume around 300k so far, that's pathetic. Company need's to find a way to Nasdaq. Financing is welcomed but not enough for company to get some love. Biggest hurdle is to get out of OTC, there will be no international interest before that.
Today is the last day for R/S
Waiting for PR
C'mon Kim
Here comes the Santa rally, break 1.39 and it can fast track to 1.5
Good to be loaded
Now is the perfect time for KT to make an 100/1 reverse split, clock is ticking by end of year.
Push SP to $10 so it can drop back to $5 and company is ready to uplist to Nasdaq.
It's the only way to go and get some international investors interest.
TIC TOC
PDS0203 combines the utility of the Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune® platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a vaccine that may more effectively prevent COVID-19.
In January of 2020 the world saw the emergence of the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.
Coronaviruses mostly infect animals, including birds and mammals. In humans, they mostly cause mild respiratory infections. However, some recent human coronavirus infections have resulted in lethal endemics, which include the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) endemics. Reported studies suggest that SARS-CoV-2 is similar to SARS-CoV based on analysis of the full-length genome. Various studies of SARS-CoV infection suggest a protective role of both antibody and T-cell immune responses. Multiple reports suggest that antibodies generated against SARS-CoV, were highly prevalent in SARS-CoV-infected patients. Although effective, the antibody response was determined to be short-lived in convalescent SARS-CoV patients. In contrast, T-cell responses have been shown to provide long-term protection more than ten years after infection. PDS Biotech is utilizing the unique immunological properties of Versamune® to develop a transformative vaccine that induces both antibodies and T-cells against the virus.
PDS0203 is currently in pre-clinical development.
Added yesterday @1.37, today tried to ad @1.28 not getting any. Avg @1.79
$HEPA Mcap 99M, cash on hand 90M
$1.18 will be absolute bottom, pps will not go under it this time around
I got plenty of dry powder. Kraig at Mcap of $68M is interesting low but they need to get R/S and Nasdaq listing for investing in.
Finnish some how "competitor" Spinnova is valued at €646M, waiting cheaper price to get in after IPO. Large scale manufacturing is around 5 years away at spinn
Made an entrance here, looks interesting company!
So let's start a parabolic flight
$LILM to the blue sky!
Sava back to the moon! I have been adding around ma200. Initial entrance was back in $1, but sold those cheapies too early. Not going to happen this time. Let the rise to begin to first target price $215!
Nice bull flag breakout on daily chart, Breaking past $13.48 next stop around $25
China’s securities regulator signals willingness to work with US over audit inspections https://www.asianewsday.com/chinas-securities-regulator-signals-willingness-to-work-with-us-over-audit-inspections/
Nail in the head Theprofessor, at OTC no one cares, whole wide world is out of shares. This is USA only company nowadays. Nasdaq and company will get some love. Bring on the reverse split Kim, I am sitting on cash for that.
Lead Drug Candidate
CRV431, a cyclophilin inhibitor
NASH
• Severe form of fatty liver disease affects about 17 million people in the US
• No approved drugs for treatment of NASH
• May result in liver cirrhosis, liver transplant, liver cancer, death
• Huge market potential projected to reach $54 Billion USD by 2027
CASH ON HAND
$115.4 M
as of 3/31/21
SHARES 76.2M
APPROX. BURN RATE
PER QUARTER $5-6 M
will increase as
Phase 2b NASH trial
progress is made
Enough cash on hand to cover all costs of programs
through end of Phase 2b (about 3 years in cash),
assuming no expansion into other areas/projects
https://hepionpharma.com/wp-content/uploads/2021/07/2021-Hepion-Fact-Sheet-FINAL.pdf
Market Cap 110 M
$HEPA
Nice double bottom. Added more.
This is crazy undervalued. Cash on hand 120M, no depth and Mcap only 115M. Added more again at 1.5x